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Abstract
Background: Lung cancer diagnosis in tissue material with commonly used histological techniques is sometimes
inconvenient and in a number of cases leads to ambiguous conclusions. Frequently advanced immunostaining
techniques have to be employed, yet they are both time consuming and limited. In this study a proteomic
approach is presented which may help provide unambiguous pathologic diagnosis of tissue material.
Methods: Lung tissue material found to be pathologically changed was prepared to isolate proteome with fast
and non selective procedure. Isolated peptides and proteins in ranging from 3.5 to 20 kDa were analysed directly
using high resolution mass spectrometer (MALDI-TOF/TOF) with sinapic acid as a matrix. Recorded complex spectra
of a single run were then analyzed with multivariate statistical analysis algorithms (principle component analysis,
classification methods). In the applied protocol we focused on obtaining the spectra richest in protein signals
constituting a pattern of change within the sample containing detailed information about its protein composition.
Advanced statistical methods were to indicate differences between examined groups.
Results: Obtained results indicate changes in proteome profiles of changed tissues in comparison to
physiologically unchanged material (control group) which were reflected in the result of principle component
analysis (PCA). Points representing spectra of control group were located in different areas of multidimensional
space and were less diffused in comparison to cancer tissues. Three different classification algorithms showed
recognition capability of 100% regarding classification of examined material into an appropriate group.
Conclusion: The application of the presented protocol and method enabled finding pathological changes in tissue
material regardless of localization and size of abnormalities in the sample volume. Proteomic profile as a complex,
rich in signals spectrum of proteins can be expressed as a single point in multidimensional space and than
analysed using advanced statistical methods. This approach seems to provide more precise information about a
pathology and may be considered in futer evaluation of biomarkers for clinical applications in different pathology.
Multiparameter statistical methods may be helpful in elucidation of newly expressed sensitive biomarkers defined
as many factors “in one point”.
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Cancer diagnosis based on standard histological meth-
ods is widely described and used in medicine. However,
most of the procedures derive from a subjective assess-
ment of observed changes and in some cases may be
inconclusive. In practical terms, new, objective methods
in cancer diagnosis are still needed especially in respect
of their sensitive. Moreover, tumour growth in its early
stages is restricted to only a part of the tissue and in
some cases it may be overlooked. Recently, proteomics
has proved to be a valuable approach in biomarker
detection and finding sensitive parameters which indi-
cate disease process [1-4]. The combination of spectro-
scopic methods of high resolution (mass spectroscopy,
nuclear magnetic resonance) with advanced statistical
methods leads to an increased likelihood of developing
new applications for diagnostic purposes [5-9]. Molecu-
lar imaging techniques described in literature as well as
profiling and detailed characterisation of biomarker
methods tend to prove their usefulness [10-12]. How-
ever, many protocols while focusing on details and theo-
retical aspects, do not translate directly into practical
applications since a large number of samples need to be
tested to validate them. Molecular imaging with mass
spectrometry may offer ample possibilities in practical
usage yet in the future rather than at present, because
of extent of time necessary for analysis, workload of
instruments, and poor image resolution in comparison
to other methods [13-15].
Our work suggests an option of proteomic profiling of
biological materials which focuses on obtaining spectra
rich in proteins that may reveal the proteomic composi-
tion of tissue. Using multivariate statistical methods
each complex spectrum can be shown as a single point
in multidimensional space (as a single parameter), then
analysed in respect of localization in this space. The sin-
gle point in multidimensional space become a specific
biomarker if its location does not match the control
region. Even a slight change in tissue structure and the
nature of pathology of any origin should be reflected in
proteomic profile, provided that profiles richest in func-
tional proteome of mass range of 3.5 - 20 kDa (without
high abundant proteins - large proteins) are obtained.
These profiles may correspond to a type of the patholo-
gical change (cancer, inflammation) as well as to normal
profiles. The obtained profiles form something like a
“proteomic fingerprint” and allow for classification of
tested materials into appropriate groups using statistical
methods. Tissue models have to be built for a known
lung tissue structure (normal, changed: cancer, inflam-
mation) using supervised classification methods. These
methods indicate also signals typical for both normal
and pathological tissue (table 1). Once appropriate
models are calculated, any unknown lung tissue material
can be measured and classified into defined groups (pre-
viously built models). The appearance of signals typical
for a pathology results in classification of examined tis-
sue into an appropriate model. This appears to be a
simple protocol without complex, time consuming and
expensive procedures which seems to be relevant con-
sidering a large number of samples needed for future
models validation.
Methods
Materials
Segments of specimens collected for an intraoperative
consultation were examined. Only lung cancer suspected
samples were taken into consideration. Diagnosis was
made basing on segments prepared with a standard crio-
static technique followed by revision on the basis of par-
affin method from specimens stained with hematoxilin
and eozine (HE) and complemented with immunohisto-
chemical method. Pathological changes in tissues were
classified according to The Word Health Organization
classification. Types of pathology are listed in table 2.
All the material for proteomic examination was col-
lected from tissue fragments which did not show necro-
sis in volume in a macroscopic examination.
The control group (15 different cases) consisted of
pathologically unchanged fragments of the lung tissue
obtained from lungs removed during surgery on trauma
cases. The material did not show any histological
changes in histological examination that followed.
Methods
Mass spectra were recorded in a linear mode of 3.1 -
20 kDa with a high resolution mass spectrometer of
time of flight type (MALDI-TOF/TOF) Bruker version
Autoflex III Smartbeam with 200 Hz laser technology.
Sinapic acid (SA) of proteomic grade (Bruker) was used
as a matrix. 400 mg of lung tissue was directly frozen at
-80°C. Next, just before measurement, the material was
defrozen, homogenized with 0.7 ml 0.9% NaCl solution
and centrifuged at 13,000 rpm for 10 minutes. The
obtained supernatant of 0.6 ml was treated with 50μlo f
10% trifluoracetic acid (TFA) and centrifuged again and
then it was transferred to Amicon Ultracel (Millipore)
centrifugal filter of 3 kDa selectivity and centifuged at
13,000 rpm to decrease the volume to 50 μl. The con-
centrated solution containing proteins and peptides was
desalted by twice repeated centrifugation in the same
conditions with 450 μl of deionized water. Concentrated
and desalted material of 10 μl was transferred to a coni-
cal tube and gently mixed with 20 μl of saturated SA
(SA in water with 0.1% TFA and acetonitryl with 0.1%
TFA at a ratio of 60:40). The obtained mixture was
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following solvent evaporation.
The instrument operated under control of FlexControl
software (Bruker).
All the statistical calculations were done using Clin-
ProtTols ver. 2.2 software (Bruker). Proteomic profiles
were analyzed with principle component analysis algo-
rithm (PCA) to observe differences in proteome profiles
of particular groups. Supervised classification algorithms,
Support Vector Machine (SVM), Genetic Algorithm
(GA) and Supervised Neural Network (SNN) were used
for classification of tissue signals into appropriate groups.
Table 1 Peak statistics - comparison of statistically important (p value of T-test/ANOVA < 0.05) peaks for data
separation and recognition capability (biomarkers candidates)
Mass (Da) Mean (Control) Mean (Pathological) P value T-Test/ANOVA P value Wilcoxon/Kruskal-Wallis Difference Average
8616.14 0.32 1.45 < 0.000001 0.00000847 < 0.000001
6228.05 1.55 4.07 < 0.000001 0.00152 < 0.000001
5759.35 1.54 2.65 < 0.000001 0.00017 0.000773
3588.09 1.99 4.82 < 0.000001 0.00017 < 0.000001
7596.85 0.81 2.11 < 0.000001 0.00154 < 0.000001
5201.26 1.93 3.87 < 0.000001 0.000366 < 0.000001
4156.39 2.08 4.87 < 0.000001 0.00017 0.0000021
9554.61 0.78 1.99 0.00000228 0.11 < 0.000001
12350.75 0.25 1.22 0.00000228 0.0000289 < 0.000001
3603.83 2.11 4.11 0.0000024 0.0162 < 0.000001
6723.40 20.93 8.96 0.00000228 0.00000855 0.000101
11297.49 0.45 0.97 0.00000228 0.00807 < 0.000001
10268.09 0.59 1.56 0.00000341 0.000314 < 0.000001
10525.25 0.3 1.19 0.00000695 0.00017 < 0.000001
5800.39 1.79 3.82 0.00000122 0.195 < 0.000001
5910.05 1.78 3.59 0.00000596 0.00375 < 0.000001
10403.69 0.47 1.43 0.000225 0.000331 < 0.000001
8297.66 0.95 1.62 0.000225 0.176 < 0.000001
4570.52 4.96 7.49 0.000296 0.106 < 0.000001
9440.24 0.71 1.08 0.000296 0.11 < 0.000001
6656.68 6.27 2.07 0.000608 0.00000986 < 0.000001
11325.26 0.67 1.09 0.00168 0.488 < 0.000001
9172.09 34.55 12.13 0.00171 0.00017 < 0.000001
7042.18 23.45 5.42 0.00252 0.0000902 < 0.000001
6020.90 5.33 2.28 0.00252 0.00017 < 0.000001
11185.69 0.75 1.19 0.00252 0.891 < 0.000001
4995.04 2.28 3.87 0.00409 0.162 < 0.000001
8456.35 1.25 2.82 0.00517 0.31 < 0.000001
9960.78 0.78 1.82 0.0059 0.211 < 0.000001
7283.97 39.59 7.2 0.00715 0.000151 < 0.000001
7249.02 2.69 1.77 0.00757 0.0042 0.00064
7173.62 4.21 7.46 0.00935 0.647 < 0.000001
5711.21 4.23 6.21 0.00935 0.441 < 0.000001
9378.33 1.82 1 0.00935 0.00238 < 0.000001
4048.24 4.11 7.16 0.0141 0.176 < 0.000001
5837.80 2.19 3.04 0.0197 0.423 < 0.000001
3907.34 41.93 14.71 0.021 0.00771 < 0.000001
10840.50 0.99 2.24 0.0231 0.149 0
6745.30 2.08 1.56 0.0392 0.0221 0.00817
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MS analysis in 100 (15 control, 85 pathological) tissue
i s o l a t e sw a sd o n e .R e s u l t sa sc o m b i n e ds p e c t r ai ng e l
view mode are shown in figure 1.
All the spectra were analyzed with PCA algorithm and
resulting data distribution in three-dimensional space
view is presented in figure 2. Rounded points are the
control group profiles and are marked for reasons of
clarity.
Statistical analysis of all profiles for biomarker discovery
revealed 39 masses of statistical importance (p < 0.005)
which influenced division of investigated groups. Results
are listed in table 1.
Proteome profiles were classified using three different
supervised algorithms. Data for both (X1 - control, X2 -
pathological) and recognition capability are listed in
table 3.
Discussion
The proteomic investigation as a novel technique for
biomarker discovery in disease process requires applica-
tion of dedicated solutions including both advanced
instruments and software. However, separation and con-
centration procedure are crucial for protein analysis
[16]. Proteins of interest are a minority in comparison
to a huge number of large structural proteins and other
compounds which may negatively influence identifica-
tion process especially in complex biological materials
(blood, tissue) [17]. Moreover, mass spectroscopy with
matrix associated laser desorption ionization, has its
limitations: lack of highly abundant proteins in a sample,
lack of salts, need for appropriate analytic concentra-
tions, etc [18]. A number of protocols are described in
literature for separation, concentration and desalting of
proteins, however most of them are costly and time
consuming [19-21]. We found that for peptides/proteins
profiles purposes, considering the nature (composition -
structure) of materials, it was enough to isolate only a
limited range of proteins which could be presented as a
single point in multidimensional space basic on
Table 2 Types f pathological change diagnosed in
examined material
Diagnosis Number of cases
Squamous cell carcinoma 25
Adenocarcinoma 27
Large cell carcinoma 4
Typical carcinoid 1
Large cell neuroendocrine carcinoma 3
Small cell carcinoma 2
Adenosquamous carcinoma 4
Sarconiatoid carcinoma 4
Bening tumors 2
Metastasis 2
Lymphoma 2
Ectopic tissue and tumor-like lesions 9
Figure 1 MS spectra in gel view mode: a) control group, b) pathologically changed tissues.
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recorded during measurement merge into one “signal”
(a point located in multidimensional space) which can
be treated as a specific biomarker. The obtained profiles
(single points) become characteristic “fingerprints” for
tissue composition. Any pathological changes in the
examined material result in different localization in
comparison to unchanged material what can be easy
seen. Depending on the extent of pathological changes
in tissue structure, proteins isolation procedure should
include either more or fewer separation steps to obtain
fractions which then can be successfully analyzed sepa-
rately. In our approach we performed a simple isolation
procedure based on precipitation of large proteins and
then filtration using filters of cut-off level 3 kDa to con-
centrate and desalt peptides/proteins. This procedure
allowed us to collect proteins in such a form that they
can be measured directly in spectrometer without any
expensive and time consuming procedures. As a detail
examination of structure of particular peptides/proteins
differentiating points distribution in multidimensional
space was not our intent, we focused on reproducibility
of this procedure. Our aim was to analyse profiles and
compare them rather then to analyse a particular com-
pound of which the profile was composed. Figure 1 pre-
sents spectra of all 100 samples, including control
tissues (A) and pathologically changed (B) in gel view
mode in order to combine all of them in one Figure 1.
The data combination reveals that common signals may
be noted in broad spectrum for both groups but patho-
logical samples are even more complex in ranges
between common bands. Signals in the same masses are
most likely typical for the tissue origin (lung) and they
reflect common to some extend structure for both types
of the same tissues (pathological and normal). The mul-
tivariate statistical method enabled to distinguish normal
samples from those diagnosed with cancer as well as
those which indicate other pathological changes (table
2). As we were aware that signals typical for pathological
Figure 2 The result of principle component analysis (PCA). Data distribution in three-dimensional space (PC1 - PC2- PC3). Points of control
group were rounded.
Table 3 Classification results
Algorithm Validation Recognition
capability
XVal X1 X2
Support Vector Machine
(SVM)
95.8% 98.8% 92.9% 100%
Genetic Algorithm (GE) 95.3% 97.7% 92.9% 100%
Supervised Neural Network
(SNN)
88.7% 98.8% 78.6% 100%
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sue which is present in material in every tumour growth
in an unchanged form, we decided to examine a rela-
tively large tissue segment of 400 mg, covering normal
and pathological region. This facilitated testing specifi-
city and sensitivity of the method with view to an early
pathological change detection (in case the change can-
not be seen macroscopically).
Recorded MS data typically comprise a large number
of signals which makes it impossible to tell the differ-
ence between examined groups basing on direct raw MS
spectra. However, the principle component analysis
(PCA) algorithm enables to present complex spectrum
in a single point located in multidimensional space. This
location is strictly defined by sample composition, and
the points representing spectra can be easily compared.
The result of PCA analysis of all the samples shown in
Figure 2 revealed different localization of normal and
pathological samples. Moreover, pathological samples
were more dispersed in space which could be explained
by the fact that many different types of cancer were
examined. We found 39 different masses (table 1) which
are of statistical importance and discriminate all the
data. The examination of compounds structure is a typi-
cal approach and has been widely described in refer-
ences. We found that as much as 39 masses influence
samples distribution in multidimensional space and all
of them may be important for change identification.
A typical approach based on a single, one-parametrical
statistical investigation seems to be less efficient com-
pared to multiparametrical methods especially in respect
of sensitivity and selectivity. Also we attempted to point
out that there was no need to precisely define (protein
structure identification) each of 39 signals because all of
them are strictly defined by the point located in multidi-
mensional space (non - dimensional data x, y, z). Points
obtained from PCA calculations can be then classified
and compared using different classification algorithms
(table 3). In our experiment the recognition capability of
the tree most common models was 100% which may
demonstrate a high specificity of the procedure.
Conclusions
The proteomic investigation of tissue samples using
advanced statistical methods enabled differentiation of
lung tissue with cancer and unchanged tissue material
even in an early stage of growth (low pathologcial to
unchanged tissue ratio in sample). Following ist valida-
tion, this method, supporting commonly used histologi-
c a lt e c h n i q u e s ,m a yb ec o n s i dered an objective, precise
and fast procedure in an early cancer diagnosis. Our
protocol may be useful in procedures that need a large
number of samples due to the elimination of time con-
suming steps. Multiparameter statistical methods may
be helpful in elaboration of newly defined biomarkers
for clinical applications expressed as many factors “in
one point”.
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